<DOC>
	<DOCNO>NCT01048814</DOCNO>
	<brief_summary>The purpose study improve upon validate prognostic and/or predictive accuracy drug response marker development improve alternative algorithm base actual clinical outcome retrospective case .</brief_summary>
	<brief_title>Retrospective Case Study Validate Existing Chemoresponse Marker Test Ovarian , Peritoneal Fallopian Cancer Cases</brief_title>
	<detailed_description>This multicenter , retrospective chart review study de-identified drug response marker result limit data set clinical outcome data . Data approximately 512 case collect approximately 30 site correlate secondary endpoint identify order produce train set incorporate additional improvement exist ChemoFx score system . The outcome progression free survival define period time first dose chemotherapy follow report marker result clinical progression death . Objective response measure first dose chemotherapy follow report marker result progression change therapy .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<criteria>Case original pathology report show , epithelial ovarian , peritoneal , fallopian tube carcinoma . Cases must meet one follow classification : Recurrent : Complete Response follow primary therapy period absence measurable disease ; Persistent : Partial Response follow 6 cycle platinum base therapy measurable disease remain Refractory : Stable Disease Progressive Disease primary platinum therapy . Case must commercial ChemoFx drug response marker final report Cases evidence synchronous primary endometrial cancer past history primary endometrial cancer exclude unless follow condition meet : Stage great IB ; Less 3 mm invasion without vascular lymphatic invasion ; No poorly differentiate subtype , include papillary serous , clear cell , FIGO Grade 3 lesion .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>